Literature DB >> 2783066

Circumscribed choroidal hemangiomas.

R Anand1, J J Augsburger, J A Shields.   

Abstract

We report observations of 71 patients with circumscribed choroidal hemangiomas. Each of these patients had a unilateral choroidal tumor with characteristic ophthalmoscopic, fluorescein angiographic, and ultrasonographic features. The affected patients ranged in age from 9 to 86 years when diagnosed. Sixty-four (90%) of the 71 patients were followed up by use after their initial diagnostic examination. The median follow-up was 45.5 months (range, 6 weeks to 12 years). Forty-two of the 64 patients were treated with scatter photocoagulation to the tumor surface on one or more occasions for vision-impairing or vision-threatening nonrhegmatogenous retinal detachment. The subretinal fluid resolved following photocoagulation in all of these eyes, and the vision stabilized in 34 patients (53%). However, the visual acuity at the most recent follow-up was less than 6/15 in 46 (72%) of the 64 affected eyes. Scatter photocoagulation, as employed in this group of patients, frequently results in retinal reattachment and temporary visual improvement, but many patients have permanently decreased vision in the affected eye, particularly when the tumor or the retinal detachment affects the foveal area. One third of the patients with 6/60 or better visual acuity at presentation are estimated to deteriorate to less than 6/60 visual acuity within 10 years.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783066     DOI: 10.1001/archopht.1989.01070020408045

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  24 in total

1.  Transpupillary thermotherapy in the treatment of circumscribed choroidal hemangiomas.

Authors:  Raul N G Vianna; Luiza Fernandes; Acácio Muralha; Aderbal Alves Júnior; Lilia Muralha; Eduardo Muranaka
Journal:  Int Ophthalmol       Date:  2004-03       Impact factor: 2.031

Review 2.  The role of photodynamic therapy in the treatment of symptomatic choroidal hemangioma.

Authors:  Bernhard Jurklies; Norbert Bornfeld
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-02-08       Impact factor: 3.117

3.  Results of external beam radiotherapy for diffuse choroidal hemangiomas in Sturge-Weber syndrome.

Authors:  Matthieu Randon; Christine Lévy-Gabriel; Rachid Abbas; Rémi Dendale; Livia Lumbroso; Laurence Desjardins; Nathalie Cassoux
Journal:  Eye (Lond)       Date:  2018-02-06       Impact factor: 3.775

4.  Application of intravitreal bevacizumab for circumscribed choroidal hemangioma.

Authors:  Min Sagong; Junyeop Lee; Woohyok Chang
Journal:  Korean J Ophthalmol       Date:  2009-06-09

5.  Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma.

Authors:  B Jurklies; G Anastassiou; S Ortmans; A Schüler; H Schilling; U Schmidt-Erfurth; N Bornfeld
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

6.  Long-term results after low dose ocular irradiation for choroidal haemangiomas.

Authors:  H Schilling; W Sauerwein; A Lommatzsch; W Friedrichs; S Brylak; N Bornfeld; A Wessing
Journal:  Br J Ophthalmol       Date:  1997-04       Impact factor: 4.638

7.  Long-term (4 years) results of choroidal hemangioma treated with proton beam irradiation.

Authors:  A Zeisberg; I Seibel; D Cordini; N Lakotka; G Willerding; L Moser; J Heufelder; A M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-04-29       Impact factor: 3.117

Review 8.  Photodynamic therapy of circumscribed choroidal haemangioma.

Authors:  A D Singh; P K Kaiser; J E Sears; M Gupta; P A Rundle; I G Rennie
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

9.  Vascular tumors of the retina and choroid: diagnosis and treatment.

Authors:  Mary E Turell; Arun D Singh
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

10.  [Photodynamic therapy for choroidal hemangioma. Long-term results].

Authors:  S Michels; R Michels; A Beckendorf; U Schmidt-Erfurth
Journal:  Ophthalmologe       Date:  2004-06       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.